EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tixagevimab-Cilgavimab Effectively Prevents COVID-19 Infection in Patients with End-Stage Kidney Disease

Noppakao Kongtal iD, Watchara Pichitsiri, Supinda Sirilak iD, Anyarin Wannakittirat iD, Busakorn Sontham, Sagoontee Inkate iD, Theerachai Thammathiwat iD

Viruses · 2025

DOI: 10.3390/v17091216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Noppakao Kongtal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Faculty of Medicine, Naresuan University, Phitsanulok 65000, Thailand. Hauptthemen laut MEDLINE: COVID-19, Kidney Failure, Chronic, COVID-19 Drug Treatment. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with end-stage kidney disease (ESKD) often exhibit suboptimal responses to COVID-19 vaccination. Tixagevimab-Cilgavimab, a neutralizing long-acting antibody (LAAB), has demonstrated effectiveness in preventing severe COVID-19 and hospitalization among immunocompromised populations. This study aimed to evaluate the efficacy and safety of Tixagevimab-Cilgavimab in ESKD patients receiving hemodialysis, peritoneal dialysis, or kidney transplantation. This single-center, retrospective cohort study was conducted at Naresuan University Hospital, Phitsanulok, Thailand, and included patients with end-stage kidney disease (ESKD) receiving maintenance hemodialysis, peritoneal dialysis, or kidney transplantation between June 2022 and June 2023, during the peak of the Omicron variant. Patients who received a single 150/150 mg dose of Tixagevimab-Cilgavimab were compared to those who did not, in terms of time to first COVID-19 infection and hospitalization within 6 months. Cox proportional hazards models were used to evaluate associations, adjusted for age, sex, type 2 diabetes, dyslipidemia, systolic and diastolic blood pressure, serum creatinine, number of COVID-19 vaccine doses, and prior COVID-19 infection. Safety was assessed by comparing creatine kinase (CK) levels before and after treatment using generalized estimating equations (GEE). Of 117 patients, 58 received Tixagevimab-Cilgavimab (mean age 59 ± 15 years); 92% were on dialysis and 8% had undergone kidney transplantation. COVID-19 infection occurred in 10.3% of the LAAB group versus 11.9% in the control group. In the adjusted Cox model, LAAB use was significantly associated with a reduced risk of COVID-19 infection (adjusted HR: 0.20; 95% CI: 0.04–0.95; p = 0.043). No variables were significantly associated with hospitalization, although LAAB use showed a non-significant trend toward reduced hospitalization risk (adjusted HR: 0.08; 95% CI: 0.01–1.56; p = 0.096). No local or systemic adverse effects were reported. CK levels remained unchanged after administration. Tixagevimab-Cilgavimab was effective in reducing the risk of COVID-19 infection among ESKD patients, without evidence of adverse effects, supporting its use as a prophylactic agent in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Kidney Failure, ChronicCOVID-19 Drug TreatmentHumansMaleFemaleMiddle AgedRetrospective StudiesAgedSARS-CoV-2Renal DialysisAntibodies, Monoclonal, HumanizedThailandAdultHospitalizationKidney TransplantationAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19dialysisend-stage kidney diseaselong-acting antibody

Substanzen

Antibodies, Monoclonal, HumanizedAntibodies, Neutralizing

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Faculty of Medicine, Naresuan University, Phitsanulok 65000, Thailand.
  • Excellence Center in Renal Care, Naresuan University Hospital, Faculty of Medicine, Naresuan University, Phitsanulok 65000, Thailand.
  • Renal Unit, Nursing Department, Naresuan University Hospital, Phitsanulok 65000, Thailand.
  • Department of Family Medicine, Faculty of Medicine, Naresuan University, Phitsanulok 65000, Thailand.

ORCID-Profile: Noppakao Kongtal, Supinda Sirilak, Anyarin Wannakittirat, Sagoontee Inkate, Theerachai Thammathiwat

Zitieren

APA

Kongtal, N., Pichitsiri, W., Sirilak, S., Wannakittirat, A., Sontham, B., Inkate, S., & Thammathiwat, T. (2025). Tixagevimab-Cilgavimab Effectively Prevents COVID-19 Infection in Patients with End-Stage Kidney Disease. Viruses. https://doi.org/10.3390/v17091216

Vancouver

Kongtal N, Pichitsiri W, Sirilak S, Wannakittirat A, Sontham B, Inkate S, et al. Tixagevimab-Cilgavimab Effectively Prevents COVID-19 Infection in Patients with End-Stage Kidney Disease. Viruses. 2025. doi:10.3390/v17091216

BibTeX
@article{Kongtal2025,
  author = {Kongtal, Noppakao and Pichitsiri, Watchara and Sirilak, Supinda and Wannakittirat, Anyarin and Sontham, Busakorn and Inkate, Sagoontee and Thammathiwat, Theerachai},
  title = {Tixagevimab-Cilgavimab Effectively Prevents COVID-19 Infection in Patients with End-Stage Kidney Disease},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17091216}
}
Kostenlos starten →